Akari Therapeutics Plc Current ratio
Что обозначает Current ratio в Akari Therapeutics Plc?
Current ratio Akari Therapeutics Plc является 3.73
Какое определение для Current ratio?
Коэффициент текущей ликвидности - это коэффициент ликвидности, который измеряет, достаточно ли у компании ресурсов для выполнения своих краткосрочных обязательств.
The current ratio is an indication of a company's liquidity and measures the capability to meet a company's short-term obligations. It compares a firm's current assets to its current liabilities, and is expressed as current assets divided by current liabilities. The ratio is only useful when two companies are compared within industry because inter industry business operations differ substantially. To determine liquidity, the current ratio is not as helpful as the quick ratio, because it includes all those assets that may not be easily liquidated, like prepaid expenses and inventory.
Acceptable current ratios vary from industry to industry. In many cases an investor would consider a high current ratio to be better than a low current ratio, because a high current ratio indicates that the company is more likely to pay the investor back. Large current ratios are not always a good sign for investors. If the company's current ratio is too high it may indicate that the company is not efficiently using its current assets or its short-term financing facilities. If current liabilities exceed current assets the current ratio will be less than 1. A current ratio of less than 1 indicates that the company may have problems meeting its short-term obligations.
Some types of businesses can operate with a current ratio of less than one however. If inventory turns into cash much more rapidly than the accounts payable become due, then the firm's current ratio can comfortably remain less than one. Inventory is valued at the cost of acquiring it and the firm intends to sell the inventory for more than this cost. The sale will therefore generate substantially more cash than the value of inventory on the balance sheet. Low current ratios can also be justified for businesses that can collect cash from customers long before they need to pay their suppliers.
Current ratio компаний в Health Care сектор на NASDAQ по сравнению с Akari Therapeutics Plc
Что делает Akari Therapeutics Plc?
akari is a clinical-stage biopharmaceutical company focused on the development and commercialization of innovative therapeutics to treat orphan autoimmune and inflammatory diseases. akari’s lead drug, coversin, a second-generation and potentially best-in-class complement inhibitor, acts on complement component-c5, preventing release of c5a and formation of c5b – 9 (also known as the membrane attack complex or mac). coversin is a recombinant small protein (16,740 da) derived from a native protein discovered in the saliva of the ornithodoros moubata tick, where it modulates the host immune system to allow the parasite to feed without alerting the host to its presence or provoking an immune response.
Компании с current ratio похож на Akari Therapeutics Plc
- Ping An Healthcare and Technology имеет Current ratio из 3.72
- Azimut Exploration имеет Current ratio из 3.72
- VBG AB (publ) имеет Current ratio из 3.73
- Goldshore Resources имеет Current ratio из 3.73
- Silicon Motion Technology Corp имеет Current ratio из 3.73
- FriendTimes имеет Current ratio из 3.73
- Akari Therapeutics Plc имеет Current ratio из 3.73
- Goliath Resources имеет Current ratio из 3.73
- Nichols Plc имеет Current ratio из 3.73
- Titan Medical имеет Current ratio из 3.73
- Great Northern Minerals имеет Current ratio из 3.73
- Tootsie Roll Industries имеет Current ratio из 3.73
- Innate Pharma S.A имеет Current ratio из 3.73